Abstract
This article presents some real-life challenges faced by clinical trial Data Monitoring Committees (DMCs), with the aim of clarifying some of the controversial issues that relate to both statistical stopping boundaries and DMC decision-making. Specific attention is given to what constitutes a sensible statistical boundary for stopping a trial early for benefit, bearing in mind that one usually needs proof beyond reasonable doubt of a treatment benefit sufficient to alter future clinical practice. Appropriate choices of stopping boundary for harm and futility are also discussed. The examples serve to illustrate that the practicalities of DMC decision-making require wise judgements based on a totality of evidence, making any statistical boundary just an objective guideline rather than a definitive stopping rule.
Keywords
HarmBoundary (topology)Clinical trialGuidelineData monitoring committeeEarly stoppingComputer scienceMedicineManagement scienceIntensive care medicinePsychologyArtificial intelligenceSocial psychologyMathematicsEconomics
Affiliated Institutions
Related Publications
Cumulative Meta-Analysis of Therapeutic Trials for Myocardial Infarction
Cumulative meta-analysis of therapeutic trials facilitates the determination of clinical efficacy and harm and may be helpful in tracking trials, planning future trials, and mak...
Randomized trials stopped early for benefit: a systematic review.
RCTs stopped early for benefit are becoming more common, often fail to adequately report relevant information about the decision to stop early, and show implausibly large treatm...
More flexible sequential and non-sequential designs in long-term clinical trial
In this paper, we describe decision making procedures as they exist in most clinical trials,review some recently suggested approaches to monitoring and clarify how these methods...
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
The protocol of a clinical trial serves as the foundation for study planning, conduct, reporting, and appraisal. However, trial protocols and existing protocol guidelines vary g...
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Abstract Background: Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials...
Publication Info
- Year
- 2006
- Type
- article
- Volume
- 3
- Issue
- 6
- Pages
- 513-521
- Citations
- 82
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
82
OpenAlex
Cite This
Stuart Pocock
(2006).
Current controversies in data monitoring for clinical trials.
Clinical Trials
, 3
(6)
, 513-521.
https://doi.org/10.1177/1740774506073467
Identifiers
- DOI
- 10.1177/1740774506073467